Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease
These findings highlight the importance of early ILD detection and management so patients can receive, and potentially benefit from, subsequent anti-HER2 targeted therapies. ILD recurrence/exacerbation during subsequent therapies was low in patients who experienced ILD with T-DXd.
Authors
- Kazuhito Shiosakai
- Yuji Hirakawa
- Toshiro Mizuno (ORCID: https://orcid.org/0000-0002-3922-8251)
- Yoshiaki Shinden (ORCID: https://orcid.org/0000-0003-1545-3697)
- Hirofumi Terakawa (ORCID: https://orcid.org/0000-0002-9475-190X)
- Junji Tsurutani
- Takashi Yamanaka
- Akiyo Yoshimura
- Kazuki Nozawa
- Mitsugu Yamamoto
- Jun Hashimoto
- Toru Mukohara
- Shigenori E. Nagai
- Yasuyuki Kojima
- Makoto Wakahara
- Tetsuhiko Taira
- Kazuo Matsuura
- Hiroji Iwata
- Toshimi Takano
- Takahiro Nakayama
Institutions
- Kagoshima University (JP)
- SHOWA Medical University (JP)
- Daiichi Sankyo (Germany) (DE)
- Kanagawa Prefectural Hospital Organization (JP)
- Nagoya City University (JP)
- St. Luke's International Hospital (JP)
- Osaka International Cancer Institute (JP)
- Kanazawa University Hospital (JP)
- Daiichi-Sankyo (Japan) (JP)
- Mie University Hospital (JP)
- Kagoshima University Hospital (JP)
- Kagoshima City Hospital (JP)
- Saitama Cancer Center (JP)
- Tottori University Hospital (JP)
- Aichi Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Japan Cancer Society (JP)
- Japanese Foundation For Cancer Research (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- The Breast
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.breast.2026.104722
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Daiichi-Sankyo
- Daiichi Sankyo Europe